Lurbinectedin is a chemotherapy drug that is used to treat certain types of cancer. According to the FDA label [2], Lurbinectedin can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women, and animal studies have shown fetal harm. Therefore, Lurbinectedin should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.

Women of reproductive potential should use effective contraception during treatment with Lurbinectedin and for at least six months after the last dose. Lurbinectedin can also affect male fertility, so men should use effective contraception during treatment and for at least four months after the last dose [2].

The FDA label also recommends that breastfeeding should be avoided during treatment with Lurbinectedin and for at least seven days after the last dose [2]. It is not known whether Lurbinectedin is excreted in human milk or if it affects the breastfed infant.

In conclusion, Lurbinectedin can cause fetal harm when administered to a pregnant woman. Women of reproductive potential should use effective contraception during treatment with Lurbinectedin and for at least six months after the last dose. Breastfeeding should be avoided during treatment with Lurbinectedin and for at least seven days after the last dose [2].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] https://medlineplus.gov/druginfo/meds/a620049.html